Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis
| Autor: | Valeria Raia, M. Collura, Luisa Romanò, G. Melzi, Massimo Antonelli, Giovanna Pisi, A. Manca, B. Santini, S. Bertasi, L. Di Febbraro, P. Rosati, I. Grazioli, C.L. Pisconti, L. Ferrero, R. Ferrari, L. Iapichino, Vincenzina Lucidi, I. Esposito, A. Battistini |
|---|---|
| Přispěvatelé: | Santini, B, Antonelli, M, Battistini, A, Bertasi, S, Collura, M, Esposito, I, DI FEBBRARO, L, Ferrari, R, Ferrero, L, Iapichino, L, Lucidi, V, Manca, A, Pisconti, Cl, Pisi, G, Raia, Valeria, Romano, L, Rosati, P, Grazioli, I, Melzi, G. |
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Malabsorption Adolescent malabsorption Pancreatic Extracts Capsules Cystic fibrosis Gastroenterology Microsphere cystic fibrosis Excretion Gastrointestinal Agents Internal medicine Endopeptidases medicine Humans In patient Enteric coated Child pancreatic exocrine insufficiency Hepatology Pancrelipase business.industry Pancreatic exocrine insufficiency Drug Tolerance Lipase Patient Acceptance of Health Care medicine.disease Microspheres Amylases Exocrine Pancreatic Insufficiency Female Safety pancreatic extracts business |
| Zdroj: | Digestive and Liver Disease. 32:406-411 |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/s1590-8658(00)80261-3 |
| Popis: | Pancreatic exocrine insufficiency is a common condition in patients with cystic fibrosis. Large amounts of pancreatic enzyme supplements are required to reduce malabsorption but patient compliance is not always optimal.To compare patients' preference and the efficacy of two enteric coated microsphere preparations in patients with cystic fibrosis.Patients with pancreatic exocrine insufficiency due to cystic fibrosis.Patients were assigned to the crossover treatment with Creon or Pancrease for 1 week and then to the alternative treatment. Patients had to follow a fixed diet (at least 2 g fat/kg) and had to assume 1000 units lipase/g fat. The evaluation parameters were: patients' preference, acceptance of therapy, stool fat excretion, stool weight, gastrointestinal symptoms, and tolerance.Of the 33/60 patients who expressed a preference for one of the two treatments, 30 preferred Creon while only 3 patients preferred Pancrease (p0.001). No difference between the two treatments was observed regarding stool characteristics, gastrointestinal symptoms and tolerance. The mean number of capsules taken daily was reduced by 35% with Creon. The results of this study showed a preference in favour of Creon probably due to the reduction of daily capsule intake of 35%, supporting digestion as well as Pancrease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect